> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel To Review Amylyx ALS Drug
- URL: https://www.fdaweb.com/panel-to-review-amylyx-als-drug/
- Published: 2022-08-03T12:00:00.000Z
- Updated: 2026-09-14T17:54:33.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5152439

*Federal Register* notice: FDA has announced a 9/7 Peripheral and Central Nervous System Drugs Advisory Committee meeting. Panel members are scheduled to discuss an Amylyx Pharmaceuticals NDA for AMX0035 (sodium phenylbutyrate/taurursodiol) and its use in treating amyotrophic lateral sclerosis. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-08-03/pdf/2022-16570.pdf?ref=fdaweb.com).